Marco Donia, Research Group Leader of the TIL group at CCIT (Center for Cancer Immune Therapy) and Professor at the University of Copenhagen, shared a post on LinkedIn:
“Durable responses with TIL Cell Therapy in Patients With anti-PD-1-resistant Melanoma
Patients with advanced melanoma progressing after anti–PD-1 and BRAF/MEK inhibitor therapy face very limited options. Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) therapy, is FDA-approved since 2024.
How durable are responses to TIL therapy in patients with heavily pretreated, anti-PD-1 resistant disease?
C-144-01 is a non-randomized phase II study, 153 patients received TILs (189 enrolled), all were anti-PD-1 resistant, >80% anti-CTLA-4 resistant, 25% BRAF/MEK resistant (all those with BRAF mutation).
Key points:
- Objective response rate: 31.4% (CR: 5.9%, PR: 25.5%)
- Conversions from PR to CR can occur more than a year post-treatment
- Median Duration of Response: 36.5 months
- Responses can last >5 years
- No new safety signals (Most adverse events resolved within 30 days of treatment)
Take-home:
A single infusion of TIL therapy can induce durable responses (perhaps cure?) in a considerable proportion of patients with anti-PD-1 resistant disease
These data confirm durability of responses in the pre-PD-1 era and reinforce prior findings
Clinical implications
For patients with anti-PD-1-resistant melanoma, this study adds meaningful long-term data to support the use of TIL therapy.”
Title: Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
Authors: Theresa Medina, Jason A. Chesney, Harriet M. Kluger, Omid Hamid, Eric D. Whitman, Mike Cusnir, Sajeve S. Thomas, Martin Wermke, Evidio Domingo-Musibay, Giao Q. Phan, John M. Kirkwood, James Larkin, Jeffrey Weber, Friedrich Graf Finckenstein, Jeffrey Chou, Brian Gastman, Xiao Wu, Rana Fiaz, Amod A. Sarnaik
Read the Full Article on Journal of Clinical Oncology
More posts featuring Marco Donia.
